TY - JOUR
T1 - Classification of strokes in patients receiving intravitreal anti-vascular endothelial growth factor
AU - Starr, Matthew R.
AU - Dalvin, Lauren A.
AU - AbouChehade, Jackson E.
AU - Damento, Gena M.
AU - Garcia, Maria D.
AU - Shah, Saumya M.
AU - Hodge, David O.
AU - Meissner, Irene
AU - Iezzi, Raymond
AU - Bakri, Sophie J.
N1 - Funding Information:
Originally submitted March 22, 2018. Revision received March 22, 2018. Accepted for publication June 4, 2018. This paper was presented in part at the Association for Research in Vision and Ophthalmology meeting, May 7, 2017, Baltimore; the American Society of Retinal Specialists meeting, August 15, 2017, Boston; and the Retina Society meeting, October 7, 2017, Boston. This study was made possible using the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health under Award Number R01AG034676. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by Research to Prevent Blindness, New York, and the VitreoRetinal Surgery Foundation, Minneapolis. None of the funding sources had any involvement in study design; collection, analysis, or interpretation of the data; writing the report; or the decision to submit for publication. Dr. Iezzi is a consultant to and receives non-financial support from Alcon outside the submitted work. Dr. Bakri is a consultant to and receives nonfinancial support from Allergan, Genentech, Novartis, Roche, and Zeiss outside the submitted work. The remaining authors report no relevant financial disclosures. Address correspondence to Sophie J. Bakri, MD, or Raymond Iezzi, MD, Mayo Clinic, Department of Ophthalmology, 200 First Street SW, Rochester, MN 55905; email: bakri.sophie@mayo.edu or iezzi.raymond@mayo. edu. doi: 10.3928/23258160-20190503-14
Publisher Copyright:
© 2019 Slack Incorporated. All rights reserved.
PY - 2019
Y1 - 2019
N2 - BACKGROUND AND OBJECTIVE: The purpose of this study was to identify the differences in the types of strokes seen in patients receiving intravitreal anti-vascular endothelial growth factor (VEGF) compared with normal control populations. PATIENTS AND METHODS: We performed a retrospective consecutive review of all patients receiving intravitreal anti-VEGF injections in Olmsted County, Minnesota, from January 1, 2004, to December 31, 2013, for exudative age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), or retinal vein occlusion (RVO). A 2-year follow-up period was required for study inclusion. Three age- and sex-matched cohorts were identified. RESULTS: A total of 2,541 patients were examined. There were 690 patients identified during the study period as receiving an intravitreal injection for AMD, DME, PDR, or RVO. Of these patients, 38 (5.8%) suffered a stroke after starting intravitreal injection therapy. Of these strokes, 27 (71.1%) were ischemic, six (15.8%) were embolic, and five (13.2%) were hemorrhagic. There were no differences in the types of strokes identified among the patients receiving intravitreal injections between the case cohort and the control cohorts (P > .05 for all). CONCLUSION: The authors’ data suggest there is no predilection to the development of ischemic infarcts or hemorrhagic strokes in those patients receiving intravitreal anti-VEGF compared with control populations.
AB - BACKGROUND AND OBJECTIVE: The purpose of this study was to identify the differences in the types of strokes seen in patients receiving intravitreal anti-vascular endothelial growth factor (VEGF) compared with normal control populations. PATIENTS AND METHODS: We performed a retrospective consecutive review of all patients receiving intravitreal anti-VEGF injections in Olmsted County, Minnesota, from January 1, 2004, to December 31, 2013, for exudative age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), or retinal vein occlusion (RVO). A 2-year follow-up period was required for study inclusion. Three age- and sex-matched cohorts were identified. RESULTS: A total of 2,541 patients were examined. There were 690 patients identified during the study period as receiving an intravitreal injection for AMD, DME, PDR, or RVO. Of these patients, 38 (5.8%) suffered a stroke after starting intravitreal injection therapy. Of these strokes, 27 (71.1%) were ischemic, six (15.8%) were embolic, and five (13.2%) were hemorrhagic. There were no differences in the types of strokes identified among the patients receiving intravitreal injections between the case cohort and the control cohorts (P > .05 for all). CONCLUSION: The authors’ data suggest there is no predilection to the development of ischemic infarcts or hemorrhagic strokes in those patients receiving intravitreal anti-VEGF compared with control populations.
UR - http://www.scopus.com/inward/record.url?scp=85066284676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066284676&partnerID=8YFLogxK
U2 - 10.3928/23258160-20190503-14
DO - 10.3928/23258160-20190503-14
M3 - Article
C2 - 31100168
AN - SCOPUS:85066284676
SN - 2325-8160
VL - 50
SP - E140-E157
JO - Ophthalmic Surgery and Lasers
JF - Ophthalmic Surgery and Lasers
IS - 5
ER -